Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers

Pathology and Oncology Research

Volumn 6, Issue 4, 2000, Pages 256-263

  Rehman, Shazza ^a   Crow, Julie ^a   Revell, Peter A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bax; Bcl2; Breast cancer; cErbB2; Ductal carcinoma in situ; Ki67; Oestrogen receptor; p53

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PROTEIN EXPRESSION;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL CYCLE PROTEINS; DROSOPHILA PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034471655     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03187328     Document Type: Article

References (59)

1. Bcl2 heterodinerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Structure-function analysis of Blc2 protein
2. Identification of conserved domains important for homodiverizafion with Bcl2 and heterodiverization with Bax
3. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax alpha expression in tumor cells correlates with resistance towards apoptosis
4. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death
5. Tumour suppressor p53 is a direct transcriptonal activator of the human Bax gene
6. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients
7. Involvement of the Bcl2 gene in human folicular lymphoma
8. Bcl2 protein is top-graphically restricted in tissues characterised by apoptotic cell death
9. Expression of Bcl2 like immunoreactivity in the normal breast and in breast cancer
10. The prevalence of Bcl2 immunoreactivity in breast carcinomas and its clinicopatholigical correlates, with particular reference to oestrogen receptor status
11. Immunocytochemical localization of Bcl2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
12. The Bcl2 protein: A prognostic indicator strongly related to p53 protein in lymphnode negative breast cancer patients
13. Apoptosis suppressing protein Bcl2 is expressed in well differentiated breast carcinomas with favourable prognosis
14. p53, guardian of the genome
15. The p53 tumour suppression gene
16. p53 mutations in human cancer
17. Down regulation of Bcl2 by p53 in breast cancer cells
18. Early expression of Bcl2 protein in the adenoma-carcinoma sequence of colorectal neoplasia
19. Immunohistochemical analysis of Bcl2 expression in transitional cell carcinoma of the bladder
20. Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancers
21. Tyrosine kinase receptor with exclusive homology to EGF receptor shares chromosomal location with neu oncogene
22. Expression of cerbB2 onco-protein in mammary and extramammary Pagets disease
23. Similarity of protein encoded by the human cerbB2 gene to epidermal growth factor receptor
24. Biomarkers in early breast neoplasia
25. cerbB2 amplification in mammary carcinoma
26. cErbB2 oncogene as a prognostic marker in breast cancer
27. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu encogene
28. Production of a mouse monclonal antibody reactive with a human nuclear antigen associated with cell proliferation
29. Relationship between EGFR, cerbB2 protein expression and ki67 immunostaining in breast cancer and hormone sensitivity
30. Ki67 immunostaining in primary breast cancer: Pathological and clinical associations
31. Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis; associations with other prognostic factors and survival
32. Ki67 immunoreactivity in breast carcinoma: Relationship to prognostic variables and short term survival
33. Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation
34. Prognostic value of steroid hormone receptor multivariate analysis of systemically untreated patients with node negative primary breast cancer
35. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer
36. The prognostic value of immunohistochemical oestrogen receptor analysis in paraffin embedded and frozen sections versus that of steroid binding assays
37. Bcl2, p53 and response to lamonifen in oestrogen receptor positive metastatic breast cancer: A southwest oncology group study
38. Ductal carcinoma in situ: A proposal for a new classification
39. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long term follow up
40. Immunohistochemical detection of oestrogen and progesterone receptors in formation fixed, paraffin embedded tissues after microwave treatment. Comparison with biochemical assay in a series of 123 breast carcinomas with determination of the positivity cut off
41. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl2
42. Bcl2 and the regulation of programmed cell death
43. Bcl2 in cancer, development and apoptosis
44. Apoptosis - Its significance in cancer and cancer therapy
45. Life, death and the pursuit of apoptosis
46. Molecular thanatopsis: A discourse on the Bcl2 family and cell death
47. Apoptosis in the pathogensis and the treatment of disease
48. Bcl2 and Bcl2 related proteins in apoptosis regulation
49. The Bcl2 gene family
50. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
51. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas
52. Expression of Bcl2, but not Bax, correlates with estrogen receptor status and tumour proliferation in invasive breast carcinoma
53. In vivo patterns of Bcl2 family protein expression in breast carcinoma in relation to apoptosis
54. Expression of Bcl2 in node negative breast cancer is associated with various prognostic factors, but does not predict response to one course of peri-operative chemotherapy
55. Bcl2 protein expression and long term survival in breast cancer
56. Bcl2 expression in the spectrum of pre-invasive breast lesions
57. Loss of Bcl2 expression in DCIS of the breast relates to poor histological differentiation and to expression of p53 and cerbB2 proteins